Rekha Sinha

2.3k total citations · 1 hit paper
18 papers, 1.8k citations indexed

About

Rekha Sinha is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Rekha Sinha has authored 18 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 9 papers in Epidemiology and 8 papers in Infectious Diseases. Recurrent topics in Rekha Sinha's work include Hepatitis C virus research (12 papers), HIV/AIDS drug development and treatment (7 papers) and Liver Disease Diagnosis and Treatment (6 papers). Rekha Sinha is often cited by papers focused on Hepatitis C virus research (12 papers), HIV/AIDS drug development and treatment (7 papers) and Liver Disease Diagnosis and Treatment (6 papers). Rekha Sinha collaborates with scholars based in United States, United Kingdom and Belgium. Rekha Sinha's co-authors include Monika Peeters, Jane Scott, Oliver Lenz, Ronald Kalmeijer, Guy De La Rosa, Maria Beumont‐Mauviel, Sivi Ouwerkerk‐Mahadevan, Ira M. Jacobson, Goedele De Smedt and Graham R. Foster and has published in prestigious journals such as The Lancet, Gastroenterology and Hepatology.

In The Last Decade

Rekha Sinha

18 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Ira M. Jacobson, Gregory J. Dore et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rekha Sinha United States	11	1.4k	1.3k	687	280	130	18	1.8k
Joseph Sasadeusz Australia	16	1.2k 0.9×	1.2k 0.9×	545 0.8×	105 0.4×	40 0.3×	38	1.5k
Sarah Maylin France	23	1.9k 1.4×	2.0k 1.5×	321 0.5×	113 0.4×	101 0.8×	76	2.2k
Jerry O. Stern United States	16	808 0.6×	686 0.5×	546 0.8×	155 0.6×	83 0.6×	47	1.1k
E. Gower Switzerland	5	1.8k 1.3×	1.7k 1.3×	444 0.6×	79 0.3×	63 0.5×	5	2.0k
Roger Trinh United States	13	1.0k 0.7×	886 0.7×	420 0.6×	125 0.4×	48 0.4×	38	1.2k
Axel Baumgarten Germany	19	718 0.5×	671 0.5×	571 0.8×	279 1.0×	67 0.5×	78	1.2k
José Vicente Fernández-Montero Spain	21	749 0.5×	712 0.5×	441 0.6×	159 0.6×	44 0.3×	59	1.1k
James Witek United States	17	606 0.4×	764 0.6×	495 0.7×	377 1.3×	48 0.4×	56	1.2k
Olle Reichard Sweden	21	1.7k 1.2×	1.5k 1.1×	211 0.3×	116 0.4×	233 1.8×	39	1.9k
Manuel García–Bengoechea Spain	9	950 0.7×	892 0.7×	237 0.3×	53 0.2×	62 0.5×	15	1.2k

Countries citing papers authored by Rekha Sinha

Since Specialization

Citations

This map shows the geographic impact of Rekha Sinha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rekha Sinha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rekha Sinha more than expected).

Fields of papers citing papers by Rekha Sinha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rekha Sinha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rekha Sinha. The network helps show where Rekha Sinha may publish in the future.

Co-authorship network of co-authors of Rekha Sinha

This figure shows the co-authorship network connecting the top 25 collaborators of Rekha Sinha. A scholar is included among the top collaborators of Rekha Sinha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rekha Sinha. Rekha Sinha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Nilsson, Anna, John Pullman, Piotr Napora, et al.. (2023). A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection. Clinical Microbiology and Infection. 29(10). 1320–1327. 9 indexed citations

Vandendijck, Yannick, Jane Scott, Dirk Heerwegh, et al.. (2022). Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS). Influenza and Other Respiratory Viruses. 16(6). 1091–1100. 3 indexed citations

Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. PMC. 5 indexed citations

Wei, Lai, Tao Han, Dongliang Yang, et al.. (2016). Simeprevir plus peginterferon/ribavirin for HCV genotype 1‐infected treatment‐naïve patients in China and South Korea. Journal of Gastroenterology and Hepatology. 31(5). 912–920. 7 indexed citations

Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study. Hepatology. 64(2). 370–380. 143 indexed citations

Lawitz, Eric, Edwin DeJesus, Eric M. Yoshida, et al.. (2015). Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2). Hepatology. 64(2). 360–369. 142 indexed citations

Lawitz, Eric, E DeJesus, Eric M. Yoshida, et al.. (2015). LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. Journal of Hepatology. 62. S264–S265. 50 indexed citations

Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2015). LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1. Journal of Hepatology. 62. S270–S270. 51 indexed citations

Jacobson, Ira M., Gregory J. Dore, Graham R. Foster, et al.. (2014). Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 384(9941). 403–413. 333 indexed citations breakdown →

10.

Manns, Michael P., Patrick Marcellin, Fred Poordad, et al.. (2014). Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 384(9941). 414–426. 278 indexed citations

11.

Forns, Xavier, Eric Lawitz, Stefan Zeuzem, et al.. (2014). Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. Gastroenterology. 146(7). 1669–1679.e3. 187 indexed citations

12.

Foster, Graham R., Ira M. Jacobson, G.J. Dore, et al.. (2014). P1127 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS. Journal of Hepatology. 60(1). S456–S456. 4 indexed citations

13.

Manns, M.P., Stefan Zeuzem, Ira M. Jacobson, et al.. (2014). Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. Journal of Viral Hepatitis. 22(4). 366–375. 15 indexed citations

14.

Zeuzem, Stefan, Thomas Berg, Edward Gane, et al.. (2013). Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. Gastroenterology. 146(2). 430–441.e6. 184 indexed citations

15.

Königs, Christoph, Cornelia Feiterna‐Sperling, Susanna Esposito, et al.. (2011). Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents. AIDS. 26(4). 447–455. 13 indexed citations

16.

Cahn, Pedro, Richard Haubrich, Christine Katlama, et al.. (2010). The Impact of Baseline Characteristics on Virologic Response to Etravirine: 48-Week Pooled Analysis of Duet-1 and Duet-2. 4(5). 605–610. 7 indexed citations

17.

Kakuda, Thomas N., Monika Peeters, Chris Corbett, et al.. (2008). Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2. 46th Annual Meeting. 5 indexed citations

18.

Lazzarin, Adriano, Thomas Campbell, Bonaventura Clotet, et al.. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet. 370(9581). 39–48. 315 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact